Proteomic profiling of fatty acid binding proteins in muscular dystrophy

References

• Frayn KN. Fat as a fuel: emerging understanding of the adipose tissue-skeletal muscle axis. Acta Physiol (Oxf). 2010;199:509–518.
   PubMed Web of Science ®Google Scholar
• Jordy AB, Kiens B. Regulation of exercise-induced lipid metabolism in skeletal muscle. Exp Physiol. 2014;99:1586–1592.
   PubMed Web of Science ®Google Scholar
• Argilés JM, Campos N, Lopez-Pedrosa JM, et al. Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J Am Med Dir Assoc. 2016;17:789–796.
   PubMed Web of Science ®Google Scholar
• Hawley JA, Hargreaves M, Joyner MJ, et al. Integrative biology of exercise. Cell. 2014;159:738–749.
   PubMed Web of Science ®Google Scholar
• Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab. 2013;17:162–184.
   PubMed Web of Science ®Google Scholar
• van Hall G. The physiological regulation of skeletal muscle fatty acid supply and oxidation during moderate-intensity exercise. Sports Med. 2015;45(Suppl 1):S23–S32.
   PubMedGoogle Scholar
• Komiya Y, Sawano S, Mashima D, et al. Mouse soleus (slow) muscle shows greater intramyocellular lipid droplet accumulation than EDL (fast) muscle: fiber type-specific analysis. J Muscle Res Cell Motil. 2017;38:163–173.
   PubMed Web of Science ®Google Scholar
• Saini-Chohan HK, Mitchell RW, Vaz FM, et al. Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: thematic review series: genetics of human lipid diseases. J Lipid Res. 2012;53:4–27.
   PubMed Web of Science ®Google Scholar
• Guiraud S, Aartsma-Rus A, Vieira NM, et al. The pathogenesis and therapy of muscular dystrophies. Annu Rev Genomics Hum Genet. 2015;16:281–308.
   PubMed Web of Science ®Google Scholar
• Le Borgne F, Guyot S, Logerot M, et al. Exploration of lipid metabolism in relation with plasma membrane properties of Duchenne muscular dystrophy cells: influence of L-carnitine. PLoS One. 2012;7:e49346.
   PubMed Web of Science ®Google Scholar
• Srivastava NK, Yadav R, Mukherjee S, et al. Abnormal lipid metabolism in skeletal muscle tissue of patients with muscular dystrophy: in vitro, high-resolution NMR spectroscopy based observation in early phase of the disease. Magn Reson Imaging. 2017;38:163–173.
   PubMed Web of Science ®Google Scholar
• Srivastava NK, Yadav R, Mukherjee S, et al. Perturbation of muscle metabolism in patients with muscular dystrophy in early or acute phase of disease: in vitro, high resolution NMR spectroscopy based analysis. Clin Chim Acta. 2018;478:171–181.
   PubMed Web of Science ®Google Scholar
• Strakova J, Kamdar F, Kulhanek D, et al. Integrative effects of dystrophin loss on metabolic function of the mdx mouse. Sci Rep. 2018;8:13624.
   PubMed Web of Science ®Google Scholar
• Joseph J, Cho DS, Doles JD. Metabolomic analyses reveal extensive progenitor cell deficiencies in a mouse model of Duchenne muscular dystrophy. Metabolites. 2018;8(4):E61.
   PubMed Web of Science ®Google Scholar
• Lindsay A, Chamberlain CM, Witthuhn BA, et al. Dystrophinopathy-associated dysfunction of Krebs cycle metabolism. Hum Mol Genet. 2019;28:942–951.
   PubMed Web of Science ®Google Scholar
• Xu H, Diolintzi A, Storch J. Fatty acid-binding proteins: functional understanding and diagnostic implications. Curr Opin Clin Nutr Metab Care. 2019;22:407–412.
   PubMed Web of Science ®Google Scholar
• Landfeldt E, Edström J, Buccella F, et al. Duchenne muscular dystrophy and caregiver burden: a systematic review. Dev Med Child Neurol. 2018;60:987–996.
   PubMed Web of Science ®Google Scholar
• Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36:395–402.
   PubMed Web of Science ®Google Scholar
• Murphy S, Dowling P, Zweyer M, et al. Proteomic profiling of giant skeletal muscle proteins. Expert Rev Proteomics. 2019;16:241–256.
   PubMed Web of Science ®Google Scholar
• Constantin B. Dystrophin complex functions as a scaffold for signalling proteins. Biochim Biophys Acta. 2014;1838:635–642.
   PubMed Web of Science ®Google Scholar
• Murphy S, Ohlendieck K. The biochemical and mass spectrometric profiling of the dystrophin complexome from skeletal muscle. Comput Struct Biotechnol J. 2015;14:20–27.
   PubMed Web of Science ®Google Scholar
• Gawor M, Prószyński TJ. The molecular cross talk of the dystrophin-glycoprotein complex. Ann N Y Acad Sci. 2018;1412:62–72.
   PubMed Web of Science ®Google Scholar
• Allen DG, Whitehead NP, Froehner SC. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev. 2016;96:253–305.
   PubMed Web of Science ®Google Scholar
• Tidball JG, Welc SS, Wehling-Henricks M. Immunobiology of inherited muscular dystrophies. Compr Physiol. 2018;8:1313–1356.
   PubMed Web of Science ®Google Scholar
• Smith LR, Barton ER. Regulation of fibrosis in muscular dystrophy. Matrix Biol. 2018;68:602–615.
   PubMed Web of Science ®Google Scholar
• Villa CR, Kaddourah A, Mathew J, et al. Identifying evidence of cardio-renal syndrome in patients with Duchenne muscular dystrophy using cystatin C. Neuromuscul Disord. 2016;26:637–642.
   PubMed Web of Science ®Google Scholar
• Meyers TA, Townsend D. Cardiac pathophysiology and the future of cardiac therapies in Duchenne muscular dystrophy. Int J Mol Sci. 2019;20(17):E4098.
   PubMed Web of Science ®Google Scholar
• Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251–267.
   PubMed Web of Science ®Google Scholar
• Shieh PB. Emerging strategies in the treatment of Duchenne muscular dystrophy. Neurotherapeutics. 2018;15:840–848.
   PubMed Web of Science ®Google Scholar
• Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol. 2019;32:722–727.
   PubMed Web of Science ®Google Scholar
• Korinthenberg R. A new era in the management of Duchenne muscular dystrophy. Dev Med Child Neurol. 2019;61:292–297.
   PubMed Web of Science ®Google Scholar
• van der Vusse GJ. Albumin as fatty acid transporter. Drug Metab Pharmacokinet. 2009;24:300–307.
   PubMed Web of Science ®Google Scholar
• Glatz JF, Luiken JJ. From fat to FAT (CD36/SR-B2): understanding the regulation of cellular fatty acid uptake. Biochimie. 2017;136:21–26.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs–mechanisms and therapeutic implications. Nat Rev Endocrinol. 2015;11:592–605.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489–503.
   PubMed Web of Science ®Google Scholar
• McIntosh AL, Atshaves BP, Martin GG, et al. Effect of liver fatty acid binding protein (L-FABP) gene ablation on lipid metabolism in high glucose diet (HGD) pair-fed mice. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:985–1004.
   PubMed Web of Science ®Google Scholar
• Sikora M, Stec A, Chrabaszcz M, et al. Intestinal fatty acid binding protein, a biomarker of intestinal barrier, is associated with severity of psoriasis. J Clin Med. 2019;8(7):E1021.
   PubMed Web of Science ®Google Scholar
• Ulukan MO, Ugurlucan M, Unal O, et al. Comparisons of heart-type fatty acid-binding protein (H-FABP) levels in off-pump versus on-pump coronary artery bypass grafting. Arch Med Sci Atheroscler Dis. 2019;4:e119–e125.
   PubMedGoogle Scholar
• Shu L, Hoo RL, Wu X, et al. A-FABP mediates adaptive thermogenesis by promoting intracellular activation of thyroid hormones in brown adipocytes. Nat Commun. 2017;8:14147.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Q, Rao E, et al. Epidermal fatty acid binding protein promotes skin inflammation induced by high-fat diet. Immunity. 2015;42:953–964.
   PubMed Web of Science ®Google Scholar
• Tölle A, Suhail S, Jung M, et al. Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma. BMC Cancer. 2011;11:302.
   PubMed Web of Science ®Google Scholar
• Elsherbiny ME, Emara M, Godbout R. Interaction of brain fatty acid-binding protein with the polyunsaturated fatty acid environment as a potential determinant of poor prognosis in malignant glioma. Prog Lipid Res. 2013;52:562–570.
   PubMed Web of Science ®Google Scholar
• Stettner M, Zenker J, Klingler F, et al. The role of peripheral myelin protein 2 in remyelination. Cell Mol Neurobiol. 2018;38:487–496.
   PubMed Web of Science ®Google Scholar
• Moradi A, Forootan FS, Hosseini M, et al. Leydig cells express the FABP9 in human testis. Hum Antibodies. 2019;27:275–278.
   PubMedGoogle Scholar
• Liu RZ, Li X, Godbout R. A novel fatty acid-binding protein (FABP) gene resulting from tandem gene duplication in mammals: transcription in rat retina and testis. Genomics. 2008;92:436–445.
   PubMed Web of Science ®Google Scholar
• Thumser AE, Moore JB, Plant NJ. Fatty acid binding proteins: tissue-specific functions in health and disease. Curr Opin Clin Nutr Metab Care. 2014;17:124–129.
   PubMed Web of Science ®Google Scholar
• Hughes AL, Piontkivska H. Evolutionary diversification of the avian fatty acid-binding proteins. Gene. 2011;490:1–5.
   PubMed Web of Science ®Google Scholar
• Smathers RL, Petersen DR. The human fatty acid-binding protein family: evolutionary divergences and functions. Hum Genomics. 2011;5:170–191.
   PubMedGoogle Scholar
• Murphy S, Zweyer M, Raucamp M, et al. Proteomic profiling of the mouse diaphragm and refined mass spectrometric analysis of the dystrophic phenotype. J Muscle Res Cell Motil. 2019;40:9–28.
   PubMed Web of Science ®Google Scholar
• Kelley LA, Mezulis S, Yates CM, et al. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc. 2015;10:845–858.
   PubMed Web of Science ®Google Scholar
• Capitanio D, Viganò A, Ricci E, et al. Comparison of protein expression in human deltoideus and vastus lateralis muscles using two-dimensional gel electrophoresis. Proteomics. 2005;5:2577–2586.
   PubMed Web of Science ®Google Scholar
• Gelfi C, Viganò A, De Palma S, et al. 2-D protein maps of rat gastrocnemius and soleus muscles: a tool for muscle plasticity assessment. Proteomics. 2006;6:321–340.
   PubMed Web of Science ®Google Scholar
• Vitorino R, Ferreira R, Neuparth M, et al. Subcellular proteomics of mice gastrocnemius and soleus muscles. Anal Biochem. 2007;366:156–169.
   PubMed Web of Science ®Google Scholar
• Donoghue P, Doran P, Wynne K, et al. Proteomic profiling of chronic low-frequency stimulated fast muscle. Proteomics. 2007;7:3417–3430.
   PubMed Web of Science ®Google Scholar
• Raddatz K, Albrecht D, Hochgräfe F, et al. A proteome map of murine heart and skeletal muscle. Proteomics. 2008;8:1885–1897.
   PubMed Web of Science ®Google Scholar
• Højlund K, Yi Z, Hwang H, et al. Characterization of the human skeletal muscle proteome by one-dimensional gel electrophoresis and HPLC-ESI-MS/MS. Mol Cell Proteomics. 2008;7:257–267.
   PubMed Web of Science ®Google Scholar
• Parker KC, Walsh RJ, Salajegheh M, et al. Characterization of human skeletal muscle biopsy samples using shotgun proteomics. J Proteome Res. 2009;8:3265–3277.
   PubMed Web of Science ®Google Scholar
• Drexler HC, Ruhs A, Konzer A, et al. On marathons and sprints: an integrated quantitative proteomics and transcriptomics analysis of differences between slow and fast muscle fibers. Mol Cell Proteomics. 2012;11:M111.010801.
   PubMed Web of Science ®Google Scholar
• Gandra PG, Valente RH, Perales J, et al. Proteomic profiling of skeletal muscle in an animal model of overtraining. Proteomics. 2012;12:2663–2667.
   PubMed Web of Science ®Google Scholar
• Malik ZA, Cobley JN, Morton JP, et al. Label-free LC-MS profiling of skeletal muscle reveals heart-type fatty acid binding protein as a candidate biomarker of aerobic capacity. Proteomes. 2013;1:290–308.
   PubMedGoogle Scholar
• Geiger T, Velic A, Macek B, et al. Initial quantitative proteomic map of 28 mouse tissues using the SILAC mouse. Mol Cell Proteomics. 2013;12:1709–1722.
   PubMed Web of Science ®Google Scholar
• Burniston JG, Connolly J, Kainulainen H, et al. Label-free profiling of skeletal muscle using high-definition mass spectrometry. Proteomics. 2014;14:2339–2344.
   PubMed Web of Science ®Google Scholar
• Murgia M, Nagaraj N, Deshmukh AS, et al. Single muscle fiber proteomics reveals unexpected mitochondrial specialization. EMBO Rep. 2015;16:387–395.
   PubMed Web of Science ®Google Scholar
• Deshmukh AS, Murgia M, Nagaraj N, et al. Deep proteomics of mouse skeletal muscle enables quantitation of protein isoforms, metabolic pathways, and transcription factors. Mol Cell Proteomics. 2015;14:841–853.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Freire M, Semba RD, Ubaida-Mohien C, et al. The human skeletal muscle proteome project: a reappraisal of the current literature. J Cachexia Sarcopenia Muscle. 2017;8:5–18.
   PubMed Web of Science ®Google Scholar
• Murphy S, Zweyer M, Mundegar RR, et al. Proteomic serum biomarkers for neuromuscular diseases. Expert Rev Proteomics. 2018;15:277–291.
   PubMed Web of Science ®Google Scholar
• Szigyarto CA, Spitali P. Biomarkers of Duchenne muscular dystrophy: current findings. Degener Neurol Neuromuscul Dis. 2018;8:1–13.
   PubMed Web of Science ®Google Scholar
• Dowling P, Murphy S, Zweyer M, et al. Emerging proteomic biomarkers of X-linked muscular dystrophy. Expert Rev Mol Diagn. 2019;19:739–755.
   PubMed Web of Science ®Google Scholar
• Holland A, Carberry S, Ohlendieck K. Proteomics of the dystrophin-glycoprotein complex and dystrophinopathy. Curr Protein Pept Sci. 2013;14:680–697.
   PubMed Web of Science ®Google Scholar
• Fuller HR, Graham LC, Llavero Hurtado M, et al. Understanding the molecular consequences of inherited muscular dystrophies: advancements through proteomic experimentation. Expert Rev Proteomics. 2016;13:659–671.
   PubMed Web of Science ®Google Scholar
• Carr SJ, Zahedi RP, Lochmüller H, et al. Mass spectrometry-based protein analysis to unravel the tissue pathophysiology in Duchenne muscular dystrophy. Proteomics Clin Appl. 2018;12(2):1700071.
   PubMed Web of Science ®Google Scholar
• Capitanio D, Moriggi M, Torretta E, et al. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients. J Cachexia Sarcopenia Muscle. 2020. in press. DOI:10.1002/jcsm.12527.
   PubMed Web of Science ®Google Scholar
• Guevel L, Lavoie JR, Perez-Iratxeta C, et al. Quantitative proteomic analysis of dystrophic dog muscle. J Proteome Res. 2011;10:2465–2478.
   PubMed Web of Science ®Google Scholar
• Carberry S, Zweyer M, Swandulla D, et al. Application of fluorescence two-dimensional difference in-gel electrophoresis as a proteomic biomarker discovery tool in muscular dystrophy research. Biology (Basel). 2013;2:1438–1464.
   PubMedGoogle Scholar
• Matsumura CY, Menezes de Oliveira B, Durbeej M, et al. Isobaric tagging-based quantification for proteomic analysis: a comparative study of spared and affected muscles from mdx mice at the early phase of dystrophy. PLoS One. 2013;8:e65831.
   PubMed Web of Science ®Google Scholar
• Rayavarapu S, Coley W, Cakir E, et al. Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. Mol Cell Proteomics. 2013;12:1061–1073.
   PubMed Web of Science ®Google Scholar
• Murphy S, Zweyer M, Mundegar RR, et al. Concurrent label-free mass spectrometric analysis of dystrophin isoform Dp427 and the myofibrosis marker collagen in crude extracts from mdx-4cv skeletal muscles. Proteomes. 2015;3:298–327.
   PubMed Web of Science ®Google Scholar
• Holland A, Henry M, Meleady P, et al. Comparative label-free mass spectrometric analysis of mildly versus severely affected mdx mouse skeletal muscles identifies annexin, lamin, and vimentin as universal dystrophic markers. Molecules. 2015;20:11317–11344.
   PubMed Web of Science ®Google Scholar
• Murphy S, Brinkmeier H, Krautwald M, et al. Proteomic profiling of the dystrophin complex and membrane fraction from dystrophic mdx muscle reveals decreases in the cytolinker desmoglein and increases in the extracellular matrix stabilizers biglycan and fibronectin. J Muscle Res Cell Motil. 2017;38:251–268.
   PubMed Web of Science ®Google Scholar
• Gamberi T, Fiaschi T, Valocchia E, et al. Proteome analysis in dystrophic mdx mouse muscle reveals a drastic alteration of key metabolic and contractile proteins after chronic exercise and the potential modulation by anti-oxidant compounds. J Proteomics. 2018;170:43–58.
   PubMed Web of Science ®Google Scholar
• Dowling P, Murphy S, Ohlendieck K. Proteomic profiling of muscle fibre type shifting in neuromuscular diseases. Expert Rev Proteomics. 2016;13:783–799.
   PubMed Web of Science ®Google Scholar
• Murphy S, Zweyer M, Henry M, et al. Proteomic analysis of the sarcolemma-enriched fraction from dystrophic mdx-4cv skeletal muscle. J Proteomics. 2019;191:212–227.
   PubMed Web of Science ®Google Scholar
• Murphy S, Dowling P, Zweyer M, et al. Proteomic analysis of dystrophin deficiency and associated changes in the aged mdx-4cv heart model of dystrophinopathy-related cardiomyopathy. J Proteomics. 2016;145:24–36.
   PubMed Web of Science ®Google Scholar
• Lewis C, Jockusch H, Ohlendieck K. Proteomic profiling of the dystrophin-deficient MDX heart reveals drastically altered levels of key metabolic and contractile proteins. J Biomed Biotechnol. 2010;2010:648501.
   PubMedGoogle Scholar
• Murphy S, Zweyer M, Henry M, et al. Proteomic profiling of liver tissue from the mdx-4cv mouse model of Duchenne muscular dystrophy. Clin Proteomics. 2018;15:34.
   PubMed Web of Science ®Google Scholar
• Dowling P, Zweyer M, Raucamp M, et al. Proteomic and cell biological profiling of the renal phenotype of the mdx-4cv mouse model of Duchenne muscular dystrophy. Eur J Cell Biol. 2020;99:151059.
   PubMedGoogle Scholar
• Hathout Y, Seol H, Han MH, et al. Clinical utility of serum biomarkers in Duchenne muscular dystrophy. Clin Proteomics. 2016;13:9.
   PubMed Web of Science ®Google Scholar
• Hathout Y, Marathi RL, Rayavarapu S, et al. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Hum Mol Genet. 2014;23:6458–6469.
   PubMed Web of Science ®Google Scholar
• Coenen-Stass AM, McClorey G, Manzano R, et al. Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. Sci Rep. 2015;5:17014.
   PubMed Web of Science ®Google Scholar
• Hathout Y, Brody E, Clemens PR, et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 2015;112:7153–7158.
   PubMed Web of Science ®Google Scholar
• Murphy S, Dowling P, Zweyer M, et al. Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy. Int J Mol Med. 2017;39:1357–1370.
   PubMed Web of Science ®Google Scholar
• Spitali P, Hettne K, Tsonaka R, et al. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. J Cachexia Sarcopenia Muscle. 2018;9(4):715–726.
   PubMed Web of Science ®Google Scholar
• Parolo S, Marchetti L, Lauria M, et al. Combined use of protein biomarkers and network analysis unveils deregulated regulatory circuits in Duchenne muscular dystrophy. PLoS One. 2018;13(3):e0194225.
   PubMed Web of Science ®Google Scholar
• Hathout Y, Liang C, Ogundele M, et al. Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne muscular dystrophy. Sci Rep. 2019;9:12167.
   PubMed Web of Science ®Google Scholar
• Burch PM, Pogoryelova O, Goldstein R, et al. Muscle-derived proteins as serum biomarkers for monitoring disease progression in three forms of muscular dystrophy. J Neuromuscul Dis. 2015;2:241–255.
   PubMedGoogle Scholar
• Signorelli M, Ayoglu B, Johansson C, et al. Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle. 2019. in press. DOI:10.1002/jcsm.12517.
   PubMed Web of Science ®Google Scholar
• Grube L, Dellen R, Kruse F, et al. Mining the secretome of C2C12 muscle cells: data dependent experimental approach to analyze protein secretion using label-free quantification and peptide based analysis. J Proteome Res. 2018;17:879–890.
   PubMed Web of Science ®Google Scholar
• Lecompte S, Abou-Samra M, Boursereau R, et al. Skeletal muscle secretome in Duchenne muscular dystrophy: a pivotal anti-inflammatory role of adiponectin. Cell Mol Life Sci. 2017;74:2487–2501.
   PubMed Web of Science ®Google Scholar
• Barthélémy F, Wein N. Personalized gene and cell therapy for Duchenne muscular dystrophy. Neuromuscul Disord. 2018;28:803–824.
   PubMed Web of Science ®Google Scholar
• Shimizu-Motohashi Y, Komaki H, Motohashi N, et al. Restoring dystrophin expression in Duchenne muscular dystrophy: current status of therapeutic approaches. J Pers Med. 2019;9(1):E1.
   PubMed Web of Science ®Google Scholar
• Sun C, Serra C, Lee G, et al. Stem cell-based therapies for Duchenne muscular dystrophy. Exp Neurol. 2019;323:113086.
   PubMed Web of Science ®Google Scholar
• Min YL, Bassel-Duby R, Olson EN. CRIspr correction of Duchenne muscular dystrophy. Annu Rev Med. 2019;70:239–255.
   PubMed Web of Science ®Google Scholar
• Holland A, Schmitt-John T, Dowling P, et al. Intricate effects of primary motor neuronopathy on contractile proteins and metabolic muscle enzymes as revealed by label-free mass spectrometry. Biosci Rep. 2014;34:e00119.
   PubMed Web of Science ®Google Scholar
• Tonomura Y, Matsushima S, Kashiwagi E, et al. Biomarker panel of cardiac and skeletal muscle troponins, fatty acid binding protein 3 and myosin light chain 3 for the accurate diagnosis of cardiotoxicity and musculoskeletal toxicity in rats. Toxicology. 2012;302:179–189.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou H, Peng Q, et al. Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis. Int J Rheum Dis. 2017;20:252–260.
   PubMed Web of Science ®Google Scholar
• Lin CH, Liao CC, Huang CH, et al. Proteomics analysis to identify and characterize the biomarkers and physical activities of non-frail and frail older adults. Int J Med Sci. 2017;14:231–239.
   PubMed Web of Science ®Google Scholar
• Doran P, O’Connell K, Gannon J, et al. Opposite pathobiochemical fate of pyruvate kinase and adenylate kinase in aged rat skeletal muscle as revealed by proteomic DIGE analysis. Proteomics. 2008;8:364–377.
   PubMed Web of Science ®Google Scholar
• Gueugneau M, Coudy-Gandilhon C, Gourbeyre O, et al. Proteomics of muscle chronological ageing in post-menopausal women. BMC Genomics. 2014;15:1165.
   PubMed Web of Science ®Google Scholar
• Kim TN, Won JC, Kim YJ, et al. Serum adipocyte fatty acid-binding protein levels are independently associated with sarcopenic obesity. Diabetes Res Clin Pract. 2013;101:210–217.
   PubMed Web of Science ®Google Scholar
• Lin YL, Liou HH, Lai YH, et al. Decreased serum fatty acid binding protein 4 concentrations are associated with sarcopenia in chronic hemodialysis patients. Clin Chim Acta. 2018;485:113–118.
   PubMed Web of Science ®Google Scholar
• De Palma S, Morandi L, Mariani E, et al. Proteomic investigation of the molecular pathophysiology of dysferlinopathy. Proteomics. 2006;6:379–385.
   PubMed Web of Science ®Google Scholar
• Lippi G, Schena F, Ceriotti F. Diagnostic biomarkers of muscle injury and exertional rhabdomyolysis. Clin Chem Lab Med. 2018;57:175–182.
   PubMed Web of Science ®Google Scholar
• Motoki T, Shimizu-Motohashi Y, Saito I, et al. Renal dysfunction can occur in advanced-stage Duchenne muscular dystrophy. Muscle Nerve. 2020;61:192–197.
   PubMed Web of Science ®Google Scholar
• McKillop IH, Girardi CA, Thompson KJ. Role of fatty acid binding proteins (FABPs) in cancer development and progression. Cell Signal. 2019;62:109336.
   PubMed Web of Science ®Google Scholar
• Otaki Y, Watanabe T, Kubota I. Heart-type fatty acid-binding protein in cardiovascular disease: A systemic review. Clin Chim Acta. 2017;474:44–53.
   PubMed Web of Science ®Google Scholar
• Zhuang L, Li C, Chen Q, et al. Fatty acid-binding protein 3 contributes to ischemic heart injury by regulating cardiac myocyte apoptosis and MAPK pathways. Am J Physiol Heart Circ Physiol. 2019;316:H971–H984.
   PubMed Web of Science ®Google Scholar
• Golaszewska K, Harasim-Symbor E, Polak-Iwaniuk A, et al. Serum fatty acid binding proteins as a potential biomarker in atrial fibrillation. J Physiol Pharmacol. 2019;70:1.
   Web of Science ®Google Scholar
• Furuhashi M. Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases. J Atheroscler Thromb. 2019;26:216–232.
   PubMed Web of Science ®Google Scholar
• Dolmans LS, Rutten FH, Koenen NCT, et al. Candidate biomarkers for the diagnosis of transient ischemic attack: a systematic review. Cerebrovasc Dis. 2019;47:207–216.
   PubMed Web of Science ®Google Scholar
• Lord SJ, St John A, Bossuyt PM, et al. Setting clinical performance specifications to develop and evaluate biomarkers for clinical use. Ann Clin Biochem. 2019;56:527–535.
   PubMed Web of Science ®Google Scholar